IBI3011 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

149 results for “IBI3011”

Trials

View all 136 →

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011

64 participants · First posted Dec 19, 2025

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

250 participants · First posted May 16, 2025

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

250 participants · First posted Apr 5, 2024

Drugs

IBI3001

IBI3002

IBI318

News

Innovent Initiates First-in-Human Trial of IBI3011, Novel Anti-IL-1RAP Monoclonal Antibody for Gout Treatment

Innovent Biologics Initiates Phase 3 Trial for Novel Gout Drug Tigulixostat in China

Innovent and SanegeneBio Initiate Phase 1 Trial of IBI3016 for Hypertension

Page 1 of 15